Table 3.
Prevalence of KRAS, NRAS and BRAF mutations in North Africa
| Country Author [reference] |
Gene frequency n/N (%) | Exon frequency n/N (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| KRAS | NRAS | BRAF | KRAS Exon2 | KRAS Exon3 | KRAS Exon4 | NRAS Exon2 | NRAS Exon3 | NRAS Exon4 | BRAF Exon15 | |
| Morocco | ||||||||||
| El Agy et al. [18] | 77/210 (36.7%) | 6/210 (2.9%) | 0/210 (0%) | 68 (83.3%) | 1 (1.3%) | 8 (10.4%) | 2 (33.3%) | 4 (66.7%) | na | na |
| Houssaini et al. [19] | 22/51 (43.1%) | 1/51 (2%) | 2/51 (3.9%) | 26a (92.8%) | na | 2a (7.1%) | na | na | na | 2 (3.9%) |
| Dehbi et al. [20] | 49/114 (43%) | 6/114 (5.3%) | na | 45 (91.8%) | 3 (6.1%) | 1 (2.04%) | na | 6 (5.3%) | na | na |
| Jadda et al. [21] | 24/47 (51%) | na | 0/47 (0%) | 24 (51%) | na | na | na | na | na | 0 (0%) |
| Marchoudi et al. [22] | 22/92 (23.9%) | na | 5/92 (5.4%) | 22/92 (23.9%) | na | na | na | na | na | 5 (5.4%) |
| Bennani et al. [23] | 18/62 (29%) | na | 1/62 (1.6%) | 18 (38.7%) | na | na | na | na | na | 1 (1.6%) |
| Tunisia | ||||||||||
| Ounissi et al. [24] | 40/96 (41.7%) | 7/96 (7.3%) | na | 47b (100%) | na | na | 5c (62.5%) | 3c (37.5%) | 0c (0%) | na |
| Jouini et al. [25] | 88/129 (68.2%) | 9/129 (6.9%) | na | 84 (95.4%) | 1 (1.1%) | 3 (3.4%) | 3 (33.3%) | 4 (44.4%) | 2 (22.2%) | na |
| Chaar et al. [26] | 52/167 (31.1%) | na | na | 52 (31.1%) | na | na | na | na | na | na |
| Aissi et al. [27] | 16/51 (31.5%) | na | na | 16 (31.5%) | na | na | na | na | na | na |
| Ouerhani et al. [28] | 17/48 (35.41%) | na | na | ni | na | na | na | na | na | na |
| Sammoud et al. [29] | 12/52 (23.1%) | na | na | 12 (23.1%) | na | na | na | na | na | na |
| Bougatef et al. [30] | 22/48 (45.83%) | na | na | 22 (45.83%) | na | na | na | na | na | na |
| Bougatef et al. [31] | na | na | 4/48 (8.3%) | Na | na | na | na | na | na | 4 (8.3%) |
| Algeria | ||||||||||
| Mazouzi et al. [32] | 245/490 (50%) | 6/490d (1.2%) | na | 237 (96.7%) | 8 (3.3%) | na | na | na | na | Na |
| Boudida-Berkane K et al. [33] | 32/102 (31.4%) | na | 5/102 (4.9%) | 32 (31.4%) | na | na | na | na | na | 5 (4.9%) |
| Lybia | ||||||||||
| Abudabous et al. [34] | 13/34 (38.2%) | na | na | 13 (38.2%) | na | na | na | na | na | na |
na not available
aIn about 22 Patients with a KRAS mutations, 28 mutations were detected in exon 2 and exon 4 (Some patients have concomitant mutations)
bIn a total of 40 cases, we had 47 mutations in KRAS exon 2 (7/40 patients had 2 concomitant mutations in exon 2)
cOne of the 7 patients with NRAS mutation showed a double mutation in NRAS
dRare mutations in the NRAS gene